Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 4/20 | 0.40 |
| ▸ | ADH1A | P07327 | 4/20 | 0.40 |
| ▸ | ADH7 | P40394 | 3/20 | 0.40 |
| ▸ | ADH1C | P00326 | 3/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | ADH4 | P08319 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11764546 | 0.76 | ADH1B (0.48) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL6623400 | 0.75 | — | — | |
| SCHEMBL3914268 | 0.74 | — | — | |
| SCHEMBL270048 | 0.72 | — | — | |
| SCHEMBL3076820 | 0.70 | ADH1B (0.40) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL14327568 | 0.70 | — | — | |
| SCHEMBL269932 | 0.69 | — | — | |
| SCHEMBL6931805 | 0.69 | ADH1B (0.32) | ADH1BADH1AADH7 | |
| Formic Acid SCHEMBL7680312 | 0.67 | ALDH1A1 (0.32) | — | |
| SCHEMBL14746054 | 0.67 | ADH1B (0.41) | ADH1BADH1AADH7ADH1CEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020156292-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PHARMACIA & UPJOHN COMPANY LLC | 2002-10-24 | — | — | US | claimed |
| US-7125905-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-20050176802-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. & PHARMACIA & UPJOHN CO. | 2005-08-11 | — | — | US | disclosed |
| EP-1427326-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | SUGEN INC (US) | 2005-06-08 | — | — | EP | disclosed |
| EP-1427326-A2 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Sugen, Inc. (US) | 2004-06-16 | — | — | EP | disclosed |
| US-6573293-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. | 2003-06-03 | — | — | US | disclosed |
| WO-2003015608-A2 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | SUGEN, INC. (US) | 2003-02-27 | — | — | WO | disclosed |
| US-20020156292-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PHARMACIA & UPJOHN COMPANY LLC | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176802-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, MAP3K20, PLK2 | ADH1B 3540/4885ADH1A 2118/4885ADH7 3287/4885 |
| US-20020156292-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, MAP3K20, PLK2 | ADH1B 3540/4885ADH1A 2118/4885ADH7 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.